MART1 M26

**MART1 M26** refers to a peptide derived from the melanoma antigen recognized by T cells, known as *MART-1* (also called Melan-A), modified at position 26 (M26). MART1 M26 is used as a synthetic peptide vaccine to stimulate CD8+ T cell responses against melanoma cells in patients, particularly those expressing HLA-A*0201. It functions by targeting melanoma cells that present MART-1 on their surface via MHC Class I, thereby eliciting a cellular immune response. It is administered as part of experimental cancer vaccine protocols, often emulsified with adjuvants like Montanide and sometimes combined with cytokines such as IL-12 and GM-CSF to boost immune function. Development and testing of MART1 M26 have primarily focused on melanoma immunotherapy, aiming to induce effective tumor antigen-specific cytotoxic T lymphocyte responses in patients at high risk of relapse after surgical resection[7].

Other names

MART-1 M26MART1 M26MART 1 M26Melan-A M26